How Farxiga Treats Heart Failure
Farxiga (dapagliflozin), an SGLT2 inhibitor, reduces heart failure hospitalizations and cardiovascular death in adults with heart failure, regardless of diabetes status. It lowers the risk of worsening heart failure events by 26-30% in clinical trials like DAPA-HF and DELIVER.[1][2]
What Happens in the Body
Farxiga blocks sodium-glucose cotransporter 2 (SGLT2) proteins in the kidneys' proximal tubules. This prevents glucose and sodium reabsorption into the bloodstream, causing:
- Osmotic diuresis: Excess glucose in urine draws water out, reducing blood volume and easing heart workload without depleting potassium like loop diuretics.
- Reduced cardiac stress: Lower preload and afterload decrease filling pressures and improve cardiac efficiency.
- Metabolic shifts: Promotes ketone use as heart fuel, enhances myocardial energetics, and reduces inflammation/fibrosis.[3][4]
These effects start within days, with peak benefits over months.
Which Heart Failure Patients Benefit Most
Approved for NYHA class II-IV heart failure with reduced ejection fraction (HFrEF, ≤40%) or preserved ejection fraction (HFpEF, ≥50%). DAPA-HF showed 26% risk reduction in HFrEF; DELIVER added 17% in HFpEF.[1][2] It pairs well with ACE inhibitors, ARBs, beta-blockers, and MRAs.
Trial Data on Outcomes
| Trial | Population | Key Result |
|-------|------------|------------|
| DAPA-HF (2019) | HFrEF (± diabetes) | 26% ↓ in CV death/HF hospitalization [1] |
| DELIVER (2022) | HF with mildly reduced/preserved EF | 17% ↓ in CV death/HF events [2] |
| EMPEROR-Preserved (empagliflozin comparison) | Similar HFpEF | Farxiga matches efficacy [5] |
Real-world studies confirm sustained reductions in HF events up to 3 years.
Common Side Effects and Risks
Patients report genital infections (5-10%), dehydration, and hypotension, especially early or with diuretics. Rare risks include ketoacidosis, Fournier's gangrene, and acute kidney injury. Monitor volume status; dose is 10 mg daily.[3]
How It Compares to Other HF Drugs
| Drug/Class | Mechanism | HF Benefit | Key Difference from Farxiga |
|------------|-----------|------------|-----------------------------|
| Entresto (sacubitril/valsartan) | ARNI | ↓ HF hospitalization | Targets neurohormones; Farxiga adds diuresis/metabolism |
| Verquvo (vericiguat) | sGC stimulator | ↓ CV death | For high-risk HFrEF; Farxiga broader use |
| Jardiance (empagliflozin, another SGLT2i) | Same | Similar 25% risk ↓ | Head-to-head trials show equivalence [5] |
Guidelines (ACC/AHA 2022) rank SGLT2 inhibitors as first-line with ARNI/beta-blockers.[6]
Who Makes Farxiga and Access Details
AstraZeneca manufactures it. List price ~$500/month (US), but copay cards lower to $25 for eligible patients. Patents expire 2025-2032 in major markets; generics unlikely before 2026.[7]
Sources
[1]: NEJM - DAPA-HF
[2]: NEJM - DELIVER
[3]: Farxiga Prescribing Information
[4]: Nature Reviews Cardiology - SGLT2i Mechanisms
[5]: Lancet - EMPEROR-Preserved
[6]: ACC/AHA HF Guidelines
[7]: DrugPatentWatch - Farxiga